Federal Prisons Naloxone Access Act of 2025

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6789 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
                                H. R. 6789

To amend title 18, United States Code, to require the Bureau of Prisons 
      to ensure the availability of opioid antagonists at Federal 
                        correctional facilities.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           December 17, 2025

  Mrs. Foushee (for herself, Mrs. McBath, and Mr. Johnson of Georgia) 
 introduced the following bill; which was referred to the Committee on 
                             the Judiciary

_______________________________________________________________________

                                 A BILL


 
To amend title 18, United States Code, to require the Bureau of Prisons 
      to ensure the availability of opioid antagonists at Federal 
                        correctional facilities.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Federal Prisons Naloxone Access Act 
of 2025''.

SEC. 2. AVAILABILITY OF OPIOID ANTAGONISTS.

    Chapter 303 of title 18, United States Code, is amended--
            (1) by adding at the end the following:
``Sec. 4052. Availability of opioid antagonists
    ``(a) In General.--The Director of the Bureau of Prisons shall 
ensure that--
            ``(1) an adequate number of opioid antagonist kits are 
        maintained at each correctional facility administered by the 
        Bureau, and such kits are available in--
                    ``(A) medical housing units;
                    ``(B) staff breakrooms; and
                    ``(C) visiting areas, living quarters, recreation 
                spaces, dining halls, housing units, work and program 
                locations, hallways, corridor posts, security 
                checkpoints, any area where incarcerated people 
                congregate, and educational and religious areas;
            ``(2) that each such opioid antagonist kit is maintained 
        appropriately, including storage--
                    ``(A) in appropriate conditions at room temperature 
                and out of direct sunlight; and
                    ``(B) in a secure area that is accessible to 
                personnel of the facility;
            ``(3) that incarcerated persons are able to access such 
        opioid antagonist kits to administer to those who are 
        overdosing; and
            ``(4) in the case of any opioid antagonist kit with an 
        expiration date, that such kit is regularly checked to 
        determine if there is a need to replace it.
    ``(b) Training.--The Director shall ensure that the personnel and 
incarcerated persons of each correctional facility administered by the 
Bureau receive annual training from medical staff of the Bureau of 
Prisons on the administration of opioid antagonists, including guidance 
on recognizing any signs or symptoms of an opioid overdose.
    ``(c) Documentation.--The Director shall ensure that, with regard 
to each administration of an opioid antagonist at a correctional 
facility, the following are recorded:
            ``(1) The location of the administration.
            ``(2) The time of the administration.
            ``(3) The name of the individual that the opioid antagonist 
        was administered to.
            ``(4) The name and title of the person that administered 
        the opioid antagonist and the status of the individual to whom 
        the opioid antagonist was administered.
    ``(d) No Liability for Administration.--No incarcerated person may 
be held liable for the administration of an opioid antagonist kit in 
good faith.
    ``(e) Report.--The Director of the Bureau of Prisons shall submit a 
report each year to Congress detailing compliance with the requirements 
of this section, including--
            ``(1) the amount of opioid antagonists available at each 
        correctional facility;
            ``(2) the number of opioid overdoses at each such facility;
            ``(3) the number of trainings under subsection (b) at each 
        such facility; and
            ``(4) the number of expired opioid antagonist kits.
    ``(f) Definitions.--In this section:
            ``(1) The term `opioid antagonist' means a medication 
        approved by the Federal Food and Drug Administration that, when 
        administered, neutralizes in whole or in part the 
        pharmacological effects of an opioid in the human body.
            ``(2) The term `opioid overdose prevention kit' means a kit 
        containing--
                    ``(A) an opioid antagonist; and
                    ``(B) a pamphlet or other written notice that 
                provides guidance on how to recognize the signs or 
                symptoms of an opioid overdose and identifies the steps 
                to take in response to a suspected opioid overdose.
            ``(3) The term `personnel' includes correctional officers, 
        medical staff, counselors, and other employees of the Bureau of 
        Prisons.
    ``(g) Authorization of Appropriations.--There are authorized to be 
appropriated:
            ``(1) for fiscal year 2026, $6,000,000, for training, 
        purchase of opioid antagonists, and the initial report;
            ``(2) for each of fiscal years 2027 and 2028, $2,000,000, 
        for maintenance of opioid antagonist kits and training, and for 
        additional reporting on the effectiveness of the program.''; 
        and
            (2) in the table of sections for such chapter, by adding at 
        the end the following:

``4052. Availability of opioid antagonists.''.
                                 <all>